Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms

The FDA’s Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search is plan­ning to re­lease some cru­cial guid­ance soon for CRISPR and gene ther­a­py de­vel­op­ers on plat­form tech­nolo­gies,

Bax­ter’s CD­MO arm, Bio­Phar­ma So­lu­tions, has an­nounced a new CEO will take the reins fol­low­ing its pro­posed sale to pri­vate eq­ui­ty com­pa­ny Ad­vent In­ter­na­tion­al and